The European Food Safety Authority (EFSA) has finalized its assessment of Lipid Nutrition’s Clarinol^® CLA in the EU’s Novel Food registration process. The Panel concludes that the safety of Clarinol^® CLA has been established. The positive opinion of the EFSA is a significant step forward in allowing Clarinol^® CLA to be used in food products throughout Europe.

The Novel Food approval is necessary to build a truly long-term, sustainable market for the ingredient’s use in foodstuffs. Once this has been acquired, it will open a new world of possibilities. The core conclusion of the EFSA Panel is that the safety of Clarinol^® has been established for the proposed intake necessary to attain the results as described by the weight management health claims, which are still under evaluation by EFSA as part of the article list of generic health claims.

This positive evaluation by EFSA of the safety of Clarinol^® is an important step in the novel food approval procedure. There is an overwhelming amount of published scientific information available about CLA, which has made this evaluation not an easy one for EFSA’s NDA Panel.

Katinka Abbenbroek CEO at Lipid Nutrition: “We are excited. This evaluation of the EFSA is an important milestone. This positive opinion will now be reviewed by the member states who will finalize the Novel Food registration process. Together with the recent GRAS approval for Clarinol^® CLA Lipid Nutrition will be able to help food companies capitalize on scientific substantiated research around weight management that largely is appreciated by their target consumer.”